INTRANASAL INTERFERON-ALPHA-2 TREATMENT OF EXPERIMENTAL RHINOVIRAL COLDS
INTRANASAL INTERFERON-ALPHA-2 TREATMENT OF EXPERIMENTAL RHINOVIRAL COLDS
复制标题
DOI：
10.1093/infdis/150.2.174
复制
发表时间：
1984-01-01
影响因子：
6.4
通讯作者：
GWALTNEY, JM
中科院分区：
文献类型：
--
作者：
HAYDEN, FG;GWALTNEY, JM
在两项随机、双盲、安慰剂对照研究中评估了重组干扰素-α2（HuIFN-α2）对39型鼻病毒实验性感染的治疗效果。成年志愿者（血清中和抗体滴度，≤1:2）给予9次。鼻病毒接种后28小时开始通过鼻内喷雾（研究1）或滴剂（研究2）给予106IU HuIFN-α2，每天3次，持续5天。在这两项研究中，HuIFN-α2 都不能预防鼻病毒感染或感冒。滴鼻剂和较小程度的喷雾治疗可显着减少病毒脱落的持续时间和数量。滴剂治疗对鼻部症状评分有显着但适度的影响，并且有鼻粘液产生量减少的趋势。尽管干扰素的鼻灰浓度较低，HuIFN-α2滴剂似乎比HuIFN-α2喷雾剂具有更高的抗病毒活性和治疗功效。显然，HuIFN-α2对于治疗自然发生的鼻病毒感冒可能没有治疗作用。
The therapeutic efficacy of recombinant interferon-.alpha.2 (HuIFN-.alpha.2) in experimental infection with rhinovirus type 39 was assessed in 2 randomized, double-blind, placebo-controlled studies. Adult volunteers (serum neutralizing antibody titer, .ltoreq. 1:2) were given 9 .times. 106 IU of HuIFN-.alpha.2 3 times a day for 5 days by intranasal spray (study 1) or drops (study 2) beginning 28 h after rhinovirus inoculation. HuIFN-.alpha.2 did not prevent rhinovirus infection or colds in either study. Treatment by nasal drops and to a lesser extent by spray was associated with significant reductions in duration and quantity of viral shedding. Treatment by drops was associated with significant but modest effects on nasal symptom scores and trends toward reduced quantities of production of nasal mucus. Despite lower nasal ash concentrations of interferon, HuIFN-.alpha.2 drops appeared to have greater antiviral activity and therapeutic efficacy than did HuIFN-.alpha.2 spray. Evidently, HuIFN-.alpha.2 may not be therapeutically useful in treating naturally occurring rhinoviral colds.